QuidelOrtho (NASDAQ:QDEL) Stock Price Up 9.4% – Here’s What Happened
QuidelOrtho (NASDAQ:QDEL) shares rose 9.4% to about $13.49 midday Thursday, after closing at $12.33. The stock traded as high as $13.55 on lighter volume (637,880 shares vs. 1.85M average). The move followed recent analyst target cuts and mixed ratings. In its May 5 earnings, the company reported Q EPS of -$0.04 vs. $0.37 expected and revenue of $619.8M vs. $665.2M.
How this was made
The 30-second read
Why it matters
QDEL’s earnings showed EPS and revenue misses versus consensus, while FY 2026 guidance was provided. The same article notes multiple downgrades/target cuts, which typically pressure valuation, yet the stock rose sharply intraday—implying traders may be focusing on guidance/positioning or interpreting analyst target cuts as less severe than prior expectations.
Market read
A large intraday move in QDEL is paired with a recent earnings miss and multiple analyst target cuts, creating a setup for continued volatility and re-assessment of near-term expectations.
What to watch
The article highlights very low/negative profitability metrics (negative net margin, negative EPS history) and a wide gap between moving averages; technical positioning could dominate near-term price action.
Background
The piece is a single-stock market-movers recap: QDEL’s mid-day jump is framed around its recent earnings (May 5) and a cluster of analyst rating/price-target changes in early May and April/February.
Ticker impact
QuidelOrtho shares jumped 9.4% while the article cites recent earnings miss and multiple analyst rating/target changes affecting QDEL’s outlook.
Likely elevated volatility near-term; upside follow-through depends on whether the market treats the analyst downgrades/targets as already priced.
The article provides a concrete catalyst set (earnings miss, FY 2026 EPS guidance, and several downgrades/target cuts) alongside a large same-day price move, but it does not identify a single definitive new fundamental event on the day.
Market effects
Diagnostics/POC testing names may see read-across volatility when a large-cap peer’s earnings/guidance disappoints and then rebounds on analyst revisions.
Primarily US-listed sentiment; limited direct regional spillover beyond healthcare diagnostics.
Global diagnostics demand signals are not directly addressed; impact is mostly company-specific.
Counterpoint
The 9.4% rally could be a short-covering/mean-reversion move after heavy selling, not a durable re-rating of fundamentals.
Key entities
- companyQuidelOrtho Corporation
NASDAQ-listed diagnostics company; subject of the article’s price-move and post-earnings/analyst-revision discussion.
- analyst_firmJefferies Financial Group
Cut QDEL from buy to hold and reduced its target price (May 7).
- analyst_firmCitigroup
Reduced its QDEL price objective and set a neutral rating (May 6).
- analyst_firmUBS Group
Reaffirmed neutral with a $12 price objective (May 7).
